Kyverna Therapeutics

company

About

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$85M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$85M
Kyverna Therapeutics has raised a total of $85M in funding over 2 rounds. Their latest funding was raised on Jan 26, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 26, 2022 Series B $85M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Kyverna Therapeutics is funded by 2 investors. Intellia Therapeutics and jVen Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Intellia Therapeutics Series B
jVen Capital Series B